Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes using stem cell and encapsulation technologies.
The partnership targets type 1 and some insulin-dependent type 2 diabetes treatments through a proprietary differentiation process converting stem cells into insulin-producing cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This process will be advanced through a research collaboration agreement (RCA).
The JV focuses on the research, development, manufacture and marketing of diabetes therapies that utilise encapsulated stem cells before, during, or after differentiation.
By combining RCA-derived stem cell expertise with the encapsulation platform of SGAustria, the companies aim to produce scalable and safe solutions worldwide.
The partners will establish a US-based company, Insulinova, to facilitate clinical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSGAustria holds an exclusive licence and may secure a future licence contingent on RCA completion, equipping the JV to address a critical health challenge.
Avant Technologies CEO Chris Winter said: “We’re thrilled to join forces with SGAustria in this game-changing JV. Merging our capital and forward-thinking strategy with their advanced biotech innovations, we’re setting the stage for revolutionary diabetes therapies that have the potential to transform countless lives.”
SGAustria contributes its cell-encapsulation technology based on over 50 peer-reviewed studies and collaborations with global biotech firms.
This technology transports, protects, isolates, and stores living cells.
Avant will offer initial funding during the upcoming eight months to meet criteria for a reproducible diabetes therapy and seek additional funding to progress towards a potential Phase I trial in the US or equivalent jurisdiction.
SGAustria CEO Brian Salmons said: “SGAustria’s encapsulation platform holds tremendous promise for reshaping cell therapies, and this JV stands as proof of that potential.
“Teaming up with Avant and a prospective RCA partner allows us to leverage our combined capabilities to deliver cutting-edge, reliable diabetes treatments, supported by our established proficiency in GMP production and cellular science.”
